Patent intelligence · US
US 10369142
Combination dosage form of a mu opioid receptor antagonist and an opioid agent
Combination dosage form of a mu opioid receptor antagonist and an opioid agent
Patent details — US 10369142
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2019
- Expiration
- Aug 1, 2039
- Applicant
- Theravance Biopharma R&D IP, LLC
- Claims
- 9
- CPC classes
- A61K, A61K31/439, A61K31/46, A61K31/485
Quick answer
US 10369142 (Combination dosage form of a mu opioid receptor antagonist and an opioid agent) is held by Theravance Biopharma R&D IP, LLC. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/439, A61K31/46, A61K31/485, A61K9/209, A61K9/282
More from Theravance Biopharma R&D IP, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 10369142?
US 10369142 (Combination dosage form of a mu opioid receptor antagonist and an opioid agent) is held by Theravance Biopharma R&D IP, LLC. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10369142?
Theravance Biopharma R&D IP, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 10369142 expire?
Our index shows an expiration date of Aug 1, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.